Photo from wikipedia
Mutant-selective IDH1 inhibitors engage their target in the brain and shrink glioma tumors with an acceptable safety profile, according to phase I trial data on three different drug candidates. However,… Click to show full abstract
Mutant-selective IDH1 inhibitors engage their target in the brain and shrink glioma tumors with an acceptable safety profile, according to phase I trial data on three different drug candidates. However, some clinicians argue the drug strategy might be futile-or even make tumor progression worse.
Keywords:
target common;
inhibitors target;
glioma;
mutation glioma;
idh inhibitors;
common mutation
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!